The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate COVID-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for US emergency use authorization.
WHO spokesperson Christian Lindmeier, asked at a UN briefing in Geneva about the drug, said: “Indeed, this is an interesting development. We would have to see the full data about it. If it holds true, then it is another weapon in the fight against the COVID-19 pandemic.”
Read the latest updates in our dedicated coronavirus section.
The treatment, molnupiravir, cut the rate of hospitalization and death by 50 percent in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released this month.
For the latest headlines, follow our Google News channel online or via the app.
Read more:
Experts predict ‘severe’ flu season once COVID-19 restrictions relaxed
WHO advises additional COVID-19 shot for immunocompromised people
AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19
Also Read
-
Experts predict ‘severe’ flu season once COVID-19 restrictions relaxed
-
UK waited too long for COVID-19 lockdown: Report
-
WHO advises additional COVID-19 shot for immunocompromised people
-
Merck applies for US emergency authorization of COVID-19 pill
-
AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19
-
More COVID-19 patients developing diabetes as pancreas cells being harmed: Experts